Howard Kaufman

Howard Kaufman has been central to clinical development of T-VEC (talimogene laherparepvec) — the first FDA-approved oncolytic viral therapy. He led the OPTiM trial demonstrating durable response benefit of intralesional T-VEC versus GM-CSF in unresectable melanoma. His work on oncolytic virus immunotherapy mechanisms and combination strategies has helped establish this modality in cancer immunotherapy.